Program
radiprodil
Also written as “Radiprodil”, “RGH-896” and “Radiprodil with Carbamazepine”.
Its studies are mostly in Tuberous Sclerosis · Neurodevelopmental Disorders · Spasms, Infantile · Pain, led by 3 companies.
Drug pageRadiprodil: every studyAll 9 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GRIN Therapeuticsits history only | 75 open or running | phase 3since Oct 31, 2025 | Feb 22, 2023 | Nov 2026phase 1 · NCT05818943 |
| UCB | 20 open or running | phase 2since Jul 8, 2016 | Jan 4, 2016 | none ahead |
| AbbVieits history only | 10 open or running | phase 2since Feb 5, 2009 | Feb 5, 2009 | none ahead |
Also a collaborator on its studies: Angelini Pharma, Avance Clinical Pty, PRA Health Sciences and Gedeon Richter.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of UCB only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 4, 2016First study: phase 1 study in Healthy VolunteersFirst studyNCT02647697 · 10 enrolled · Netherlands
- Jul 8, 2016Phase 2 study in Spasms, InfantileNCT02829827 · 3 enrolled · France
TargetBeta
“Glutamate NMDA receptor; GRIN1/GRIN2B antagonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Esketaminerule | Johnson & Johnson | phase 4 | 51 |
| Memantinerule | AbbVie | phase 4 | 29 |
Studies
All 2 UCB leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02829827Spasms, Infantile · France | 2 | Terminated | Oct 2, 2018 | 3 |
| NCT02647697Healthy Volunteers · Netherlands | 1 | Completed | Feb 2016 | 10 |
How it is read
Names in the registry
- “Radiprodil”, 6 entries
- “RGH-896”, 3 entries
- “Radiprodil with Carbamazepine”, 1 entry
- “Radiprodil with Itraconazole”, 1 entry
- “Radiprodil + co-administered drugs”, 1 entry
Conditions, from the studies’ own filings
- Tuberous Sclerosis, 3 studies
- Neurodevelopmental Disorders, 2 studies
- Spasms, Infantile, 1 study
- Pain, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.